---
title: "CQP: The clinical trial for hydrochloride prasugrel tablets has been approved"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/256724648.md"
description: "CQP announced that its holding subsidiary Chongqing Pharmaceutical has received approval from the National Medical Products Administration to conduct clinical trials for Prasugrel Hydrochloride Tablets. This medication is used to prevent cardiovascular diseases such as acute coronary syndrome and is currently marketed in over 70 countries worldwide, but has not yet been launched in China"
datetime: "2025-09-10T11:06:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/256724648.md)
  - [en](https://longbridge.com/en/news/256724648.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/256724648.md)
generator: "portal-rs"
---

# CQP: The clinical trial for hydrochloride prasugrel tablets has been approved

According to the Zhitong Finance APP, Chongqing Pharmaceutical Holdings (000950.SZ) announced that its controlling subsidiary, Chongqing Pharmaceutical (Group) Co., Ltd. (hereinafter referred to as "Chongyao Co., Ltd."), has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration (hereinafter referred to as "NMPA"). The clinical trial for Clopidogrel Hydrochloride Tablets will be conducted in the near future.

It is reported that the original manufacturer of Clopidogrel Hydrochloride Tablets is Daiichi Sankyo Company, Limited, which is a third-generation drug that inhibits ADP-induced platelet aggregation. It is indicated for the prevention of acute coronary syndrome, stable angina, and thrombosis in patients with old myocardial infarction after percutaneous coronary intervention. It has been launched in more than 70 countries and regions worldwide (not yet launched in mainland China)

### Related Stocks

- [000950.CN](https://longbridge.com/en/quote/000950.CN.md)

## Related News & Research

- [Livzon Pharma buys 3.5% Xinbeijiang Pharma stake for RMB 106.7 million](https://longbridge.com/en/news/296601614.md)
- [Oura exploring how its ring could detect brain hemorrhages after Bill Ackman suggests it could have helped his daughter](https://longbridge.com/en/news/296658401.md)
- [Dajin Heavy Industry calls extraordinary general meeting](https://longbridge.com/en/news/296615574.md)
- [08:38 ETThe 2027 NAMM Show Announces Global Five-Day Celebration of Music, Product Innovation and Industry Leadership](https://longbridge.com/en/news/296229778.md)
- [CSPC Innovation Pharmaceutical: Biopharma licensing and product launches drove record revenue and profit growth](https://longbridge.com/en/news/296129143.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**